CIP
GHDX

Champlain Investment Partners’s Genomic Health, Inc. GHDX Stock Holding History

Champlain Investment Partners’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,007,555
Closed -$30.8M – 149
2015
Q1 		$30.8M Sell
1,007,555
-209,620
-17% -$6.66M 0.53% 85
2014
Q4 		$38.9M Sell
1,217,175
-17,605
-1% -$573K 0.62% 75
2014
Q3 		$35M Sell
1,234,780
-27,310
-2% -$761K 0.61% 78
2014
Q2 		$34.6M Buy
1,262,090
+11,180
+0.9% +$298K 0.57% 79
2014
Q1 		$32.9M Buy
1,250,910
+91,815
+8% +$2.63M 0.57% 84
2013
Q4 		$33.9M Buy
1,159,095
+83,250
+8% +$2.64M 0.6% 79
2013
Q3 		$32.9M Buy
1,075,845
+111,095
+12% +$3.72M 0.62% 71
2013
Q2 		$30.6M Buy
+964,750
New +$31.7M 0.62% 66

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Champlain Investment Partners's GHDX Position: Q2 2015 in Review

Champlain Investment Partners sold out of Genomic Health, Inc. (GHDX) in Q2 2015, closing a stake of 1,007,555 shares — an estimated $30.8M sold.

Champlain Investment Partners first reported a position in GHDX in Q2 2013 and held it in 8 quarters. The position peaked at $38.9M in Q4 2014. 122 funds tracked by Wall St. Rank hold GHDX as of Q2 2015.

  • Champlain Investment Partners reported no remaining Genomic Health, Inc. position as of Q2 2015 after selling out during the quarter.
  • Champlain Investment Partners sold 1,007,555 Genomic Health, Inc. shares in Q2 2015, an estimated $30.8M.
  • Champlain Investment Partners first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 8 quarters.
  • Champlain Investment Partners's Genomic Health, Inc. position peaked at $38.9M in Q4 2014.
  • 122 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2015.

Based on Champlain Investment Partners's 13F filing for Q2 2015, filed 12 Aug 2015.